IBRX (STOCKS)
ImmunityBio, Inc. Common Stock
$7.319900
+0.329900 (+4.72%)
Prev close: $6.990000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Richard Adcock
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $7,698.05M
- Employees
- 685
- P/E (TTM)
- -8.62
- P/B (TTM)
- -8.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.08 | $-0.07 | -0.0086 | -12.04% |
|
Dec 2025 (Q4)
|
$-0.06 | $-0.10 | +0.0359 | +37.43% |
|
Sep 2025 (Q3)
|
$-0.07 | $-0.11 | +0.0402 | +36.48% |
|
Jun 2025 (Q2)
|
$-0.10 | $-0.11 | +0.0122 | +10.87% |
Financial Statements
| Revenues | $140.98M |
| Benefits Costs and Expenses | $995.47M |
| Cost Of Revenue | $933.00K |
| Costs And Expenses | $402.37M |
| Gross Profit | $140.04M |
| Nonoperating Income/Loss | -$593.11M |
| Operating Expenses | $401.43M |
| Operating Income/Loss | -$261.39M |
| Income/Loss From Continuing Operations After Tax | -$854.60M |
| Income/Loss From Continuing Operations Before Tax | -$854.50M |
| Income Tax Expense/Benefit | $108.00K |
| Net Income/Loss | -$854.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$69.00K |
| Net Income/Loss Attributable To Parent | -$854.53M |
| Net Income/Loss Available To Common Stockholders, Basic | -$854.53M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.85 |
| Diluted Earnings Per Share | -$0.85 |
| Basic Average Shares | 2,885,219,000 |
| Diluted Average Shares | 2,885,219,000 |
| Assets | $646.64M |
| Current Assets | $452.95M |
| Inventory | $547.00K |
| Other Current Assets | $452.41M |
| Noncurrent Assets | $193.68M |
| Fixed Assets | $112.79M |
| Other Non-current Assets | $80.90M |
| Liabilities | $1.52B |
| Current Liabilities | $67.95M |
| Noncurrent Liabilities | $1.45B |
| Equity | -$869.13M |
| Equity Attributable To Noncontrolling Interest | $880.00K |
| Equity Attributable To Parent | -$870.01M |
| Liabilities And Equity | $646.64M |
| Net Cash Flow From Operating Activities | -$294.39M |
| Net Cash Flow From Operating Activities, Continuing | -$294.39M |
| Net Cash Flow From Investing Activities | -$185.58M |
| Net Cash Flow From Investing Activities, Continuing | -$185.58M |
| Net Cash Flow From Financing Activities | $625.15M |
| Net Cash Flow From Financing Activities, Continuing | $625.15M |
| Net Cash Flow | $145.18M |
| Net Cash Flow, Continuing | $145.18M |
| Comprehensive Income/Loss | -$847.11M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$69.00K |
| Comprehensive Income/Loss Attributable To Parent | -$847.04M |
| Other Comprehensive Income/Loss | $7.50M |